Mabion (WAR:MAB) Beginning Cash Position: zł6.37 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MAB Mabion SA WAR:MAB
31 GF Score
Price zł7.40
GF Value zł2.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Beginning Cash Position?

Mabion WAR:MAB +0.54% 31 Beginning Cash Position is zł6.37 Mil as of Mar. 2026. GuruFocus rates WAR:MAB with a GF Score™ of 31/100 and a GF Value™ of zł2.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Mabion's Beginning Cash Position for the quarter that ended in Mar. 2026 was zł6.37 Mil.

Mabion's quarterly Beginning Cash Position declined from Sep. 2025 (zł10.76 Mil) to Dec. 2025 (zł4.61 Mil) but then increased from Dec. 2025 (zł4.61 Mil) to Mar. 2026 (zł6.37 Mil).

Mabion's annual Beginning Cash Position declined from Dec. 2023 (zł53.64 Mil) to Dec. 2024 (zł47.82 Mil) and declined from Dec. 2024 (zł47.82 Mil) to Dec. 2025 (zł38.45 Mil).

Mabion Beginning Cash Position Related Terms

Mabion Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Mabion's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion Beginning Cash Position Chart

Mabion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 48.71 53.64 47.82 38.45

Mabion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.45 23.69 10.76 4.61 6.37
WAR:MAB
31GF Score
Mabion SA WAR:MAB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of zł6.37 Mil mean?
Mabion (WAR:MAB) has a Beginning Cash Position of zł6.37 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mabion and its competitors.
Is Mabion's Beginning Cash Position too high?
Mabion's current Beginning Cash Position is zł6.37 Mil. Overall, Mabion has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Beginning Cash Position compare to VRTX and REGN?
Mabion's Beginning Cash Position of zł6.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mabion and its competitors. Mabion's current Beginning Cash Position is zł6.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.06, compared to a current price of zł7.40 — trading 259.2% above its estimated fair value. The current Beginning Cash Position is zł6.37 Mil. Mabion's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Beginning Cash Position is zł6.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.40 is trading 259.2% above its estimated GF Value™ of zł2.06. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Beginning Cash Position: zł6.37 Mil
  • GF Value™: zł2.06 vs. price of zł7.40 (259.2% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
31GF Score

Get the complete analysis for WAR:MAB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.40
Price
zł2.06
GF Value